No profile data available.
Citius Oncology, Inc. (CTOR) is a healthcare company in the blood cancer treatment drugs industry, based in Cranford, United States.
It reported revenue of $0 for fiscal year 2025, and net income of -$24.76 million. In Q3 2026 (the quarter ended June 30, 2026) revenue was $1.49 million. Its market capitalization was $88.82 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended September 30, 2025; market data as of October 9, 2026.
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey.
Citius Oncology reported $0 in revenue for fiscal year 2025. In Q3 2026 revenue was $1.49 million.
$88.82 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood cancer treatment drugs) include Lyell Immunopharma, Inc. (LYEL), Cellectis S.a. (CLLS), Atara Biotherapeutics, Inc. (ATRA), Apollomics, Inc. (APLM).